- Home
- IBIO vs AKTX Comparison
IBIO vs AKTX Comparison
Compare IBIO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- AKTX
- Stock Information
- Founded
- IBIO 2008
- AKTX N/A
- Country
- IBIO United States
- AKTX United States
- Employees
- IBIO N/A
- AKTX N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- AKTX Health Care
- Exchange
- IBIO Nasdaq
- AKTX Nasdaq
- Market Cap
- IBIO 16.4M
- AKTX 17.2M
- IPO Year
- IBIO N/A
- AKTX N/A
- Fundamental
- Price
- IBIO $1.18
- AKTX $0.47
- Analyst Decision
- IBIO Strong Buy
- AKTX Strong Buy
- Analyst Count
- IBIO 4
- AKTX 2
- Target Price
- IBIO $4.50
- AKTX $3.30
- AVG Volume (30 Days)
- IBIO 2.2M
- AKTX 472.5K
- Earning Date
- IBIO 11-12-2025
- AKTX 11-13-2025
- Dividend Yield
- IBIO N/A
- AKTX N/A
- EPS Growth
- IBIO N/A
- AKTX N/A
- EPS
- IBIO N/A
- AKTX N/A
- Revenue
- IBIO $500,000.00
- AKTX N/A
- Revenue This Year
- IBIO N/A
- AKTX N/A
- Revenue Next Year
- IBIO $33.34
- AKTX N/A
- P/E Ratio
- IBIO N/A
- AKTX N/A
- Revenue Growth
- IBIO 185.71
- AKTX N/A
- 52 Week Low
- IBIO $0.56
- AKTX $0.42
- 52 Week High
- IBIO $6.89
- AKTX $1.73
- Technical
- Relative Strength Index (RSI)
- IBIO 50.97
- AKTX 34.84
- Support Level
- IBIO $0.96
- AKTX $0.42
- Resistance Level
- IBIO $1.28
- AKTX $0.55
- Average True Range (ATR)
- IBIO 0.12
- AKTX 0.06
- MACD
- IBIO -0.03
- AKTX -0.00
- Stochastic Oscillator
- IBIO 54.68
- AKTX 24.16
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.